2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5920 Universal versus sibling HLA-matched/haplo donor-derived anti-CD7 CAR-T therapy in relapsed/refractory CD7-positive T-ALL/lbl: A single-center comparative study

Yishan Wang, Shan Fu2, Mingming Zhang, PhD3, Yali Zhou, PhD4, Jingjing Feng5, Wengang GE6, Guoqing Wei7, Jan K Davidson-Moncada8, Alex H. Zhang, Dr.9, Jiangtao Ren10, He Huang, MD, PhD11, Yongxian HU, MD12
1 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China
3 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China
4 Bioheng Therapeutics Co., Ltd., Nanjing, Jiangsu, China
5 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China
6 Bioheng Therapeutics Co., Ltd., Nanjing, Jiangsu, China
7 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China
8 Bioheng Therapeutics Co., Ltd., Nanjing, Jiangsu, China
9 Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China, Shanghai YaKe Biotechnology Ltd., Shanghai, China
10 Bioheng Therapeutics Co., Ltd., Nanjing, Jiangsu, China
11 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China
12 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, hangzhou, Zhejiang, China

Introduction:

Patients with relapsed/refractory (R/R) CD7-positive T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) have limited treatment options and poor outcomes. Anti-CD7 CAR-T therapies have demonstrated promising efficacy in this high-risk population. However, sibling HLA-matched/haplo CAR-T approaches individually manufactured, may be limited by donor availability, manufacturing time, and high-cost. Universal CAR-T products, “off-the- shelf” product, overcome these limitations. Here, we compared the safety and efficacy of universal and sibling HLA-matched/haplo donor-derived anti-CD7 CAR-T therapies in patients with R/R CD7-positive T-ALL/LBL.

 

Methods:

Universal CTD402 was engineered from third-party healthy donor T cells with targeted disruption of TCRα/β, CD7, and CIITA to enhance immune evasion and prevent alloreactivity, whereas sibling HLA-matched/haplo donor-derived CD7 CAR-T cells were generated  using endoplasmic reticulum retention technology to block the surface expression of CD7 without further genetic modifications. Patients with CD7-positive R/R T-ALL/LBL treated with anti-CD7 CAR-T therapy at Zhejiang University School of Medicine First Affiliated Hospital between 31 July, 2021 and 19 August, 2024 were retrospectively analyzed. Baseline characteristics, safety profiles, response outcomes, CAR-T cellular kinetics, subsequent allo-HSCT, and survival outcomes were compared between groups. Safety endpoints included CRS, ICANS, GvHD and infections. Efficacy endpoints included CR/CRi rate, MRD negativity, progression-free survival (PFS), and overall survival (OS). Categorical variables were compared using Fisher’s exact test, and continuous variables were compared using the Mann–Whitney U test. Survival outcomes were estimated using the Kaplan–Meier method and compared using log-rank tests.

 

Results:

A total of 35 patients with R/R CD7-positive T-ALL/LBL were included in this analysis, 20 patients treated with universal anti-CD7 CAR-T therapy (CTD402) and 15 patients treated with sibling HLA-matched/haplo donor-derived anti-CD7 CAR-T therapy. The median age was 33.5 years (range, 11–67) and 36 years (range, 20–73), respectively. Patients were heavily pretreated, with a median number of prior lines of therapy of 2 (range, 1–6) and 5 (range, 2–10), including 25% and 60% that had failed prior allo-HSCT, respectively. Patients treated with universal CAR-T had higher baseline disease burden, with a median BM blast percentage of 68.5% versus 25% and extramedullary disease present in 55% versus 20% of patients.Both universal and donor-derived CAR-T therapies demonstrated manageable safety profiles. CRS occurred in 95% and 100% of patients, with grade ≥3 CRS occurring in 2 and 0 patients, respectively (P>0.05). ICANS was observed in 0 versus 1 patient. GvHD occurred in 4 patients  receiving sibling HLA-matched/haplo donor-derived CAR-T compared with 2 patients receiving universal CAR-T (P>0.05). One patient died from tumor lysis syndrome on day 20 post infusion in universal CAR-T group.  CR/CRi achieved in 18/19 (94.7%) and 14/15 (93.3%) patients in universal and  sibling HLA-matched/haplo donor-derived CAR-T, respectively (P>0.05). Among MRD-evaluable responders, MRD negativity was observed in 100% and 92.9% of patients. With a median follow-up of 22.0 and 34.8 months in the universal and donor-derived groups, respectively, median PFS was 3.1 versus 3.6 months (p=0.573).  CAR-T cellular kinetics assessed by flow cytometry in both cohorts showed that the median peak CAR-T cell expansion was comparable between groups (p>0.05).

Conclusion:

While universal anti-CD7 CAR-T therapy achieved comparable safety and clinical efficacy  to sibling HLA-matched/haplo donor-derived CAR-T therapy, it offers advantages in accessibility, manufacturing flexibility and low costs. These findings support application of universal CAR-T strategies.

Yishan Wang: No relevant conflicts of interest to declare.